Compare KeyCorp (KEY) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Revvity Inc — how do they compare? KeyCorp trades at $22.79 (market cap $24.32B), while Revvity Inc trades at $115.25 (market cap $12.91B). The key difference: KeyCorp is the larger of the two by market cap, and KeyCorp pays the higher dividend (3.61%). Which is the better fit depends on your goals.
| KEY | RVTY | |
|---|---|---|
Market Cap | $24.32B | $12.91B |
Sector | Financials | Technology |
52-Week High | $23.99 | $117.75 |
52-Week Low | $16.78 | $82.26 |
Dividend Yield | 3.61% | 0.24% |
Enterprise Value | — | $15.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $22.68, down 0.22% on the day, with a bearish technical signal but strong fundamental recovery. The company reported Q2 2026 EPS of $0.44, beating estimates, and shows robust revenue growth to $7.29B in 2025. Recent expansion includes the acquisition of Clearwater UK, enhancing its investment banking footprint.
The outlook is positive with a consensus price target of $29.41, representing significant upside. Risks include economic uncertainty impacting loan growth and net interest income. The stock offers a dividend yield supported by consistent payouts, with analyst sentiment strongly favoring a buy rating.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
